Your browser doesn't support javascript.
loading
Crossing borders in Alzheimer's disease: A T cell's perspective.
van Olst, L; Coenen, L; Nieuwland, J M; Rodriguez-Mogeda, C; de Wit, N M; Kamermans, A; Middeldorp, J; de Vries, H E.
Affiliation
  • van Olst L; Department of Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Coenen L; Department of Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Department of Neurobiology and Aging, Biomedical Primate Research Centre, Rijswijk, The Netherlands.
  • Nieuwland JM; Department of Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Department of Neurobiology and Aging, Biomedical Primate Research Centre, Rijswijk, The Netherlands.
  • Rodriguez-Mogeda C; Department of Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • de Wit NM; Department of Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Kamermans A; Department of Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Middeldorp J; Department of Neurobiology and Aging, Biomedical Primate Research Centre, Rijswijk, The Netherlands.
  • de Vries HE; Department of Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands. Electronic address: he.devries@amsterdamumc.nl.
Adv Drug Deliv Rev ; 188: 114398, 2022 09.
Article in En | MEDLINE | ID: mdl-35780907
ABSTRACT
Alzheimer's disease (AD) is the most common form of dementia affecting millions of people worldwide. While different immunotherapies are imminent, currently only disease-modifying medications are available and a cure is lacking. Over the past decade, immunological interfaces of the central nervous system (CNS) and their role in neurodegenerative diseases received increasing attention. Specifically, emerging evidence shows that subsets of circulating CD8+ T cells cross the brain barriers and associate with AD pathology. To gain more insight into how the adaptive immune system is involved in disease pathogenesis, we here provide a comprehensive overview of the contribution of T cells to AD pathology, incorporating changes at the brain barriers. In addition, we review studies that provide translation of these findings by targeting T cells to combat AD pathology and cognitive decline. Importantly, these data show that immunological changes in AD are not confined to the CNS and that AD-associated systemic immune changes appear to affect brain homeostasis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease Limits: Humans Language: En Journal: Adv Drug Deliv Rev Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease Limits: Humans Language: En Journal: Adv Drug Deliv Rev Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2022 Document type: Article Affiliation country: